The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > ARCHIVE
ARCHIVE
- Disaster to Have No Long-term Impact on Japan Business: Chairman Barner of BI
April 18, 2011
- Hisamitsu: Acquisition of Noven Contributes to Growth in Sales
April 18, 2011
- Council Beefs Up Activities to Improve Environment for Drug Discovery in Osaka
April 18, 2011
- Operating, Net Losses Decrease: MediciNova
April 18, 2011
- Motesanib Fails to Increase OS in Non-SCC NSCLC in PIII
April 18, 2011
- EPS to Establish Wholly Owned Subsidiary in South Korea
April 18, 2011
- APA Elevates Gastric pH in PI Trial: RaQualia
April 18, 2011
- Quintiles to Expand Tokyo Laboratory
April 18, 2011
- Olmesartan + CCB Suppress CV Events in Hypertensive Patients with a History of CV Disease
April 18, 2011
- Baxter Announces Change in Storage Temperature for Advate
April 18, 2011
- Valsartan, CCB Show Similar CV Events
April 18, 2011
- JP 16th Edition Published with 106 More Drugs Added
April 18, 2011
- Korosho Announces New Schedule for NHI Price Listing
April 18, 2011
- Ethical Drug Sales Up 6.1% in February: Crecon Research & Consulting
April 18, 2011
- Takeda, DSP Announce Collaboration for Lurasidone in Europe
April 11, 2011
- AXIS Licenses Pilocarpine to Kissei for Development as Fibromyalgia Treatment: SNBL
April 11, 2011
- Prior Assessment Consultation System Started on Full Scale April 1
April 11, 2011
- DSP Licenses Anti-MRSA Drug from Takeda
April 11, 2011
- New Subsidiary in Slovenia to Manage Business in SE Europe: Astellas
April 11, 2011
- AZ Appeals to Tokyo High Court in Iressa Affair
April 11, 2011
ページ
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…